Lisbon's Octo Health launches patient-data platform in Portugal and US after €2.7M round
What's the deal? Octo Health, a Lisbon-founded healthtech, has launched its platform in Portugal and the United States simultaneously. The service lets users run blood tests across more than 110 biomarkers and pull lab results, medical history, exams, and wearable data into one place. It follows a €2.7 million pre-seed round led by 3xP GlobalDealroom has a profile for this one. Try Dealroom →.
What's the endgame? Octo wants to tackle fragmented health information, which sits scattered across providers, labs, clinical portals, and apps. The platform interprets data in each person's context, tracks indicators over time, and flags relevant changes, covering 11 health areas including cardiovascular health and metabolism.
What led to this? Founded in 2023, the company — formerly Chrono HealthDealroom has a profile for this one. Try Dealroom → — raised its pre-seed earlier this year to build a patient-controlled data platform with the US as its reference market. It offers testing through a network of partner clinics and positions its tools to complement, not replace, medical care.
Why it matters? "People are increasingly involved in managing their health, but the information they need remains scattered across different care providers, portals, and apps," said founder and chief executive officer Catarina Kemper (translated from Portuguese). "Having more data doesn't necessarily mean understanding what's relevant, what's changed, or what the next steps should be."
What could go wrong? The US expansion is commercially ambitious given that market's scale and complexity. The dual launch marks a market entry, not proof of adoption or clinical impact.
The signal: Octo joins a small cohort of Portugal-born healthtech firms reaching for international scale — Sword Health bought Germany's Kaia Health for $285 million this year. As consumers take a more active role in their own care, the race is on to consolidate fragmented health data into a single view.
Read more: jornaleconomico.sapo.pt
Image credit: Generated with Gemini
